(NASDAQ: ATYR) Atyr Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.6%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.59%.
Atyr Pharma's earnings in 2026 is -$53,324,000.On average, 10 Wall Street analysts forecast ATYR's earnings for 2026 to be -$42,792,140, with the lowest ATYR earnings forecast at -$49,964,908, and the highest ATYR earnings forecast at -$38,544,358. On average, 10 Wall Street analysts forecast ATYR's earnings for 2027 to be -$37,064,275, with the lowest ATYR earnings forecast at -$64,954,380, and the highest ATYR earnings forecast at -$3,693,834.
In 2028, ATYR is forecast to generate -$35,796,288 in earnings, with the lowest earnings forecast at -$63,955,082 and the highest earnings forecast at -$22,484,209.